These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22626986)

  • 21. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
    Franz DN; Capal JK
    Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
    Sadowski K; Kotulska K; Jóźwiak S
    Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR-related neuropathology in mutant tsc2 zebrafish: Phenotypic, transcriptomic and pharmacological analysis.
    Scheldeman C; Mills JD; Siekierska A; Serra I; Copmans D; Iyer AM; Whalley BJ; Maes J; Jansen AC; Lagae L; Aronica E; de Witte PAM
    Neurobiol Dis; 2017 Dec; 108():225-237. PubMed ID: 28888969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tuberous sclerosis complex: advances in diagnosis, genetics, and management.
    Schwartz RA; Fernández G; Kotulska K; Jóźwiak S
    J Am Acad Dermatol; 2007 Aug; 57(2):189-202. PubMed ID: 17637444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Farnesyltransferase Inhibitor Restores Cognitive Deficits in
    Sugiura H; Shimada T; Moriya-Ito K; Goto JI; Fujiwara H; Ishii R; Shitara H; Taya C; Fujii S; Kobayashi T; Hino O; Worley PF; Yamagata K
    J Neurosci; 2022 Mar; 42(12):2598-2612. PubMed ID: 35121635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nursing implications for the lifelong management of tuberous sclerosis complex.
    Agricola K; Tudor C; Krueger D; Franz DN
    J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tuberous sclerosis complex and epilepsy: recent developments and future challenges.
    Holmes GL; Stafstrom CE;
    Epilepsia; 2007 Apr; 48(4):617-30. PubMed ID: 17386056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
    Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
    Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
    Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
    Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the treatment of tuberous sclerosis complex.
    Leclezio L; de Vries PJ
    Curr Opin Psychiatry; 2015 Mar; 28(2):113-20. PubMed ID: 25602245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
    Mizuguchi M; Ohsawa M; Kashii H; Sato A
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
    Palavra F; Robalo C; Reis F
    Oxid Med Cell Longev; 2017; 2017():9820181. PubMed ID: 28386314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic update in tuberous sclerosis complex: the role of mTOR pathway inhibitors].
    Ruiz-Falcó Rojas ML
    Rev Neurol; 2012 May; 54 Suppl 3():S19-24. PubMed ID: 22605628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis.
    Waltereit R; Welzl H; Dichgans J; Lipp HP; Schmidt WJ; Weller M
    J Neurochem; 2006 Jan; 96(2):407-13. PubMed ID: 16300636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
    Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
    Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving neurobiology of tuberous sclerosis complex.
    Crino PB
    Acta Neuropathol; 2013 Mar; 125(3):317-32. PubMed ID: 23386324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
    Kenerson H; Dundon TA; Yeung RS
    Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
    Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
    Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex.
    Cambiaghi M; Cursi M; Magri L; Castoldi V; Comi G; Minicucci F; Galli R; Leocani L
    Neuropharmacology; 2013 Apr; 67():1-7. PubMed ID: 23159330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.